Krystle Nomie
Krystle Nomie has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Makhdum Ahmed
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
17 shared publications - Michael Wang
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
17 shared publications - Bingliang Fang
Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
16 shared publications - Carrie Li
Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
16 shared publications David Santos
16 shared publications- Hui Guo
Institution of Organ Transplantation, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China
16 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Supplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Supplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microenvironment that is rich in nonmalignant immune cells. We applied single-cell RNA sequencing to characterize the diverse tumor and immune cell populations of FL and identified major phenotypic subsets of FL T cells, including a cytotoxic CD4 T-cell population. We characterized four major FL subtypes with differential representation or relative depletion of distinct T-cell subsets. By integrating exome sequencing, we observed that somatic mutations are associated with, but not definitive for, reduced MHC expression on FL cells. In turn, expression of MHCII genes by FL cells was associated with significant differences in the proportions and targetable immunophenotypic characteristics of T cells. This provides a classification framework of the FL microenvironment in association with FL genotypes and MHC expression, and informs different potential immunotherapeutic strategies based upon tumor cell MHCII expression.Significance:We have characterized the FL-infiltrating T cells, identified cytotoxic CD4 T cells as an important component that is associated with tumor cell–intrinsic characteristics, and identified sets of targetable immune checkpoints on T cells that differed from FLs with normal versus low MHC expression.See related commentary by Melnick, p. 374.This article is highlighted in the In This Issue feature, p. 369
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microenvironment that is rich in nonmalignant immune cells. We applied single-cell RNA sequencing to characterize the diverse tumor and immune cell populations of FL and identified major phenotypic subsets of FL T cells, including a cytotoxic CD4 T-cell population. We characterized four major FL subtypes with differential representation or relative depletion of distinct T-cell subsets. By integrating exome sequencing, we observed that somatic mutations are associated with, but not definitive for, reduced MHC expression on FL cells. In turn, expression of MHCII genes by FL cells was associated with significant differences in the proportions and targetable immunophenotypic characteristics of T cells. This provides a classification framework of the FL microenvironment in association with FL genotypes and MHC expression, and informs different potential immunotherapeutic strategies based upon tumor cell MHCII expression.Significance:We have characterized the FL-infiltrating T cells, identified cytotoxic CD4 T cells as an important component that is associated with tumor cell–intrinsic characteristics, and identified sets of targetable immune checkpoints on T cells that differed from FLs with normal versus low MHC expression.See related commentary by Melnick, p. 374.This article is highlighted in the In This Issue feature, p. 369
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Supplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Supplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Supplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Supplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microenvironment that is rich in nonmalignant immune cells. We applied single-cell RNA sequencing to characterize the diverse tumor and immune cell populations of FL and identified major phenotypic subsets of FL T cells, including a cytotoxic CD4 T-cell population. We characterized four major FL subtypes with differential representation or relative depletion of distinct T-cell subsets. By integrating exome sequencing, we observed that somatic mutations are associated with, but not definitive for, reduced MHC expression on FL cells. In turn, expression of MHCII genes by FL cells was associated with significant differences in the proportions and targetable immunophenotypic characteristics of T cells. This provides a classification framework of the FL microenvironment in association with FL genotypes and MHC expression, and informs different potential immunotherapeutic strategies based upon tumor cell MHCII expression.Significance:We have characterized the FL-infiltrating T cells, identified cytotoxic CD4 T cells as an important component that is associated with tumor cell–intrinsic characteristics, and identified sets of targetable immune checkpoints on T cells that differed from FLs with normal versus low MHC expression.See related commentary by Melnick, p. 374.This article is highlighted in the In This Issue feature, p. 369
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microenvironment that is rich in nonmalignant immune cells. We applied single-cell RNA sequencing to characterize the diverse tumor and immune cell populations of FL and identified major phenotypic subsets of FL T cells, including a cytotoxic CD4 T-cell population. We characterized four major FL subtypes with differential representation or relative depletion of distinct T-cell subsets. By integrating exome sequencing, we observed that somatic mutations are associated with, but not definitive for, reduced MHC expression on FL cells. In turn, expression of MHCII genes by FL cells was associated with significant differences in the proportions and targetable immunophenotypic characteristics of T cells. This provides a classification framework of the FL microenvironment in association with FL genotypes and MHC expression, and informs different potential immunotherapeutic strategies based upon tumor cell MHCII expression.Significance:We have characterized the FL-infiltrating T cells, identified cytotoxic CD4 T cells as an important component that is associated with tumor cell–intrinsic characteristics, and identified sets of targetable immune checkpoints on T cells that differed from FLs with normal versus low MHC expression.See related commentary by Melnick, p. 374.This article is highlighted in the In This Issue feature, p. 369
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Supplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Supplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3. Treatment profiling of PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Freshly isolated lymphoma cells from PT2-BL-G6 and G7 PDXs. Cell viability was tested by CellTiter-Glo luminescent cell viability assay after 48-hour incubation with the indicated drug treatment. The in vitro drug and dose information for IBN and ABT-199 are listed in Supplementary Table S1. IBN, ibrutinib; PT, patient; BL, Burkitt's lymphoma.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3. Treatment profiling of PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Freshly isolated lymphoma cells from PT2-BL-G6 and G7 PDXs. Cell viability was tested by CellTiter-Glo luminescent cell viability assay after 48-hour incubation with the indicated drug treatment. The in vitro drug and dose information for IBN and ABT-199 are listed in Supplementary Table S1. IBN, ibrutinib; PT, patient; BL, Burkitt's lymphoma.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
A, Schematic describing the primary B-cell lymphoma PDX SCID/NSG-hu mouse model. Six-to 8-week-old male NSG or CB-17 SCID mice were implanted with human fetal bone. Approximately 4 to 6 weeks following bone implantation, one injection of 5 Ã- 106 patient tumor cells were administered directly into the human fetal bone chip as the first generation (G1). The levels of circulating human β2M in mouse serum were used to monitor tumor engraftment and growth in G1 mice. Once tumor burden was detected, the pieces of tumor with bone chip were subcutaneously transplanted into NSG mice as the second generation (G2). After G2, the consistent growths of tumor in NSG mice were acquired. Single-agent targeted therapy, drug-resistant treatment, or combination therapy, were administered in the indicated generations. B, Human β2M reflected the tumor burdens of 16 B-cell lymphomas in PDX-G1 mice. After 3-4 weeks of tumor inoculation, mouse sera were collected from the peripheral blood of tail vein, and the level of human β2M was determined by ELISA.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
A, Schematic describing the primary B-cell lymphoma PDX SCID/NSG-hu mouse model. Six-to 8-week-old male NSG or CB-17 SCID mice were implanted with human fetal bone. Approximately 4 to 6 weeks following bone implantation, one injection of 5 Ã- 106 patient tumor cells were administered directly into the human fetal bone chip as the first generation (G1). The levels of circulating human β2M in mouse serum were used to monitor tumor engraftment and growth in G1 mice. Once tumor burden was detected, the pieces of tumor with bone chip were subcutaneously transplanted into NSG mice as the second generation (G2). After G2, the consistent growths of tumor in NSG mice were acquired. Single-agent targeted therapy, drug-resistant treatment, or combination therapy, were administered in the indicated generations. B, Human β2M reflected the tumor burdens of 16 B-cell lymphomas in PDX-G1 mice. After 3-4 weeks of tumor inoculation, mouse sera were collected from the peripheral blood of tail vein, and the level of human β2M was determined by ELISA.